ストックスクリーナーアプリを入手
272.61
0.05%
-0.13
アフターアワーズ：
272.61
Krystal Biotech Inc (KRYS) 最新ニュース
Krystal Biotech wins FDA RMAT status for lung cancer therapy - Seeking Alpha
Krystal Biotech (KRYS) Gains FDA RMAT Status for Innovative Lung Cancer Therapy - GuruFocus
Krystal Biotech Says US FDA Grants Regenerative Medicine Advanced Therapy Designation to Lung Cancer Treatment - marketscreener.com
FDA grants RMAT designation to Krystal Biotech’s lung cancer therapy By Investing.com - Investing.com India
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of ... - Caledonian Record
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer - The Manila Times
FDA backs KB707 lung cancer immunotherapy with RMAT designation - stocktitan.net
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? - MSN
Federated Hermes Inc. Cuts Holdings in Krystal Biotech, Inc. $KRYS - MarketBeat
Vyjuvek Growth Powers Krystal Biotech’s (KRYS) Huge Upward Analyst Target Price Revision - Insider Monkey
Krystal Biotech (BIT:1KRYS) Price Target Increased by 11.47% to 252.42 - Nasdaq
Assessing Krystal Biotech (KRYS) Valuation After Analyst Optimism On Vyjuvek Expansion And Ophthalmic Pipeline - Sahm
Goldman Sachs Raises Price Target for Krystal Biotech (KRYS) | K - GuruFocus
Atle Fund Management AB Acquires 22,033 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech stock price target raised to $327 by Goldman Sachs - Investing.com Canada
Earnings Miss: Is Krystal Biotech Inc. impacted by rising ratesJuly 2025 Short Interest & Safe Entry Point Alerts - mfd.ru
Krystal Biotech, Inc. $KRYS Shares Acquired by EFG Asset Management North America Corp. - MarketBeat
Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable - sharewise.com
Clear Street raises Krystal Biotech stock price target on KB801 potential - Investing.com Canada
Are you looking for a top momentum pick? Why Krystal Biotech, Inc. (KRYS) is a great choice - MSN
Assessing Krystal Biotech (KRYS) Valuation As Analyst Upgrades And Earnings Optimism Gain Traction - Sahm
Are You Looking for a Top Momentum Pick? Why Krystal Biotech, Inc. (KRYS) is a Great Choice - Yahoo Finance
Krystal Biotech, Inc. $KRYS Shares Sold by Maryland State Retirement & Pension System - MarketBeat
SG Americas Securities LLC Cuts Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Bank of America Increases Krystal Biotech (NASDAQ:KRYS) Price Target to $318.00 - MarketBeat
KRYS Sees New Price Target as B of A Securities Raises Outlook | - GuruFocus
BofA Securities Adjusts Price Target on Krystal Biotech to $318 From $288, Maintains Buy Rating - marketscreener.com
Nasdaq Moves: Is Caribou Biosciences Inc. backed by strong institutional buyingSell Signal & Low Drawdown Investment Strategies - baoquankhu1.vn
Rate Cut: What drives Krystal Biotech Incs stock price2025 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
What does Wall Street think about Krystal Biotech (KRYS)? - MSN
Krystal Biotech, Inc. (KRYS) Stock Analysis: Evaluating the Healthcare Innovator’s Growth Potential - DirectorsTalk Interviews
What Does Wall Street Think About Krystal Biotech (KRYS)? - Finviz
Krystal Biotech (KRYS) Is Up 9.0% After Positive Interim Data From Inhaled CF Gene Therapy Study - Sahm
Krystal Biotech gets expanded FDA approval for Vyjuvek - MSN
Krystal Biotech: Beyond VYJUVEK Commercialization (NASDAQ:KRYS) - Seeking Alpha
Recent price trend in Krystal Biotech (KRYS) is your friend, here's why - MSN
Assessing Krystal Biotech (KRYS) Valuation After Strong Recent Share Price Momentum - Sahm
Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Update and CORAL-3 Plans - Sahm
Krystal Biotech Reports Strong Q3 2025 Performance - MSN
Krystal Biotech rises on new phase 1 data for cystic fibrosis asset - MSN
Activity Recap: Will Krystal Biotech Inc outperform small cap indexes2025 Institutional Moves & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Krystal Biotech (KRYS) Price Target Increased by 18.96% to 269.93 - Nasdaq
Krystal Biotech (BIT:1KRYS) Price Target Increased by 19.80% to 226.45 - Nasdaq
Movement Recap: What is Krystal Biotech Inc.’s market position2025 Short Interest & Daily Profit Maximizing Tips - baoquankhu1.vn
KRYS Stock: Citigroup Raises Price Target to $336, Maintains Buy - GuruFocus
KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives - sharewise.com
Citigroup Issues Positive Forecast for Krystal Biotech (NASDAQ:KRYS) Stock Price - MarketBeat
Avoiding Lag: Real-Time Signals in (KRYS) Movement - Stock Traders Daily
Krystal Biotech stock maintains Buy rating at H.C. Wainwright on strong revenue - Investing.com Canada
Krystal Biotech outlines rare disease growth strategy update - TipRanks
Krystal Biotech, Inc. (KRYS) Stock Analysis: Navigating A Promising 4.05% Potential Upside - DirectorsTalk Interviews
Credo Technology Group Holding And 2 Insider Picks For Strong Growth - Yahoo Finance
Krystal Biotech Reports ~$389M 2025 VYJUVEK Revenue, $955M Cash Reserves - Nasdaq
0.10%
7.16%
大文字化:
|
ボリューム (24 時間):